Skip to content

Inhibition of scar recurrence using Iow-energy fractional CO2 laser in the early postoperative period of proliferative scarring: a single-centre, randomised, self-controlled trial

Inhibition of scar recurrence using Iow-energy fractional CO2 laser in the early postoperative period of proliferative scarring: a single-centre, randomised, self-controlled trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400080140
Enrollment
Unknown
Registered
2024-01-22
Start date
2024-02-01
Completion date
Unknown
Last updated
2024-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

scar

Interventions

Conventional scar treatment group:Routine management with silicone-based gel preparations and tension reducer therapy throughout the course of treatment

Sponsors

Shanghai 9th people hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. age 18-60 years; 2. incision length over (including) 4 cm; 3. skin type III: sometimes burns and sometimes tans, common in yellow people, or type IV: rarely burns and often tans, common in yellow people; 4. patients undergoing dermatologic surgical procedures planned for one-stage suturing.

Exclusion criteria

Exclusion criteria: 1. pregnant women, women who plan to become pregnant within six months, or women who are breastfeeding; 2. abnormal complete blood count, abnormal liver or renal function; 3. history of malignancy or radiation therapy, infectious or viral skin disease, immunosuppression, prolonged systemic corticosteroid therapy, and use of any scarring treatments 4 weeks prior to the initiation of treatment; 4. known allergy to topical lidocaine anesthesia, and history of photosensitizing medications; 5. lesion Wounds or ulcers at the site; 6. Participation in other clinical trials; 7. Underlying diseases such as diabetes mellitus and hypertension.

Design outcomes

Primary

MeasureTime frame
Patient and Observer Scar Assessment Scale;

Secondary

MeasureTime frame
scar width;

Countries

China

Contacts

Public ContactJun Yang

Shanghai 9th people hospital

yj5599@Hotmail.com+86 139 0180 2159

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026